Healthcare Business Recap: Vivus Director BUYS Its Shares, Humana’s New INITIATIVE

Yesterday’s top stories:

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) reports positive results from a pre-clinical ex vivo evaluation, which could lead to the development of enhanced cellular vaccines for cancer along with chronic viral infections. Alnylam’s concentration is upon RNA interference, or the study of how genes in cells are turned on and off.

Investing Insights: Intuit Inc. Earnings: A Mixed Bag.

Shares of Vivus, Inc. (NASDAQ:VVUS) rose modestly after Director Ernest Mario reported his purchase of another 5,000 shares, which brings his position up to 45,000. This purchase was made on August 20th at a price of $20.75; the director previously acquired 20,000 shares at an average price of $21.74 earlier in August.

Humana Inc. (NYSE:HUM) announces that it is introducing its new comprehensive primary care initiative in its Centers for Medicare and Medicaid Services. This four-year, multi-payer arrangement will be set in motion across three areas, and is designed to supply more Americans with affordable, high quality health care.

Shares of Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) crater following a negative article in Seeking Alpha by contributor Apsara Biotech which implied that the Phase II results for its cancer drug Bavituximab, also known as Bavi, are “overhyped and inconclusive”. The author called the huge, 500 percent runup in the stock during the past two months “unjustified” and also said that Peregrine’s current $300 million market cap is far too high, considering what the firm is really worth.

Don’t Miss: FLA: Apple Was SUPER QUICK With Its Labor Fixes.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.